DBV Technologies (NASDAQ:DBVT) Stock Price Up 10% – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT) traded up 10% during mid-day trading on Monday . The company traded as high as $23.47 and last traded at $23.0860. 225,451 shares were traded during mid-day trading, a decline of 39% from the average session volume of 371,328 shares. The stock had previously closed at $20.99.

Wall Street Analyst Weigh In

DBVT has been the topic of a number of recent research reports. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a report on Thursday, December 18th. Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a report on Wednesday, December 17th. Guggenheim reaffirmed a “buy” rating and issued a $51.00 price target (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Citizens Jmp raised their price objective on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.25.

DBV Technologies Stock Performance

The stock has a market cap of $1.28 billion, a P/E ratio of -4.50 and a beta of -0.98. The firm has a 50 day moving average of $20.62 and a two-hundred day moving average of $15.73.

Insider Buying and Selling at DBV Technologies

In other news, major shareholder Bpifrance Epic sold 1,292,103 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the sale, the insider owned 7,303,369 shares in the company, valued at approximately $30,601,116.11. This trade represents a 15.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 3,369,627 shares of company stock valued at $15,489,908 over the last three months. 1.44% of the stock is currently owned by corporate insiders.

Institutional Trading of DBV Technologies

A number of hedge funds have recently bought and sold shares of the stock. Allworth Financial LP bought a new position in shares of DBV Technologies during the 4th quarter worth about $32,000. Royal Bank of Canada bought a new stake in shares of DBV Technologies in the fourth quarter valued at about $34,000. New York State Common Retirement Fund acquired a new stake in DBV Technologies during the third quarter worth about $34,000. GAMMA Investing LLC increased its stake in DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the period. Finally, Truvestments Capital LLC increased its stake in DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after acquiring an additional 1,620 shares during the period. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.